Why Real-World Data Is More Important than Ever
At this point of the evolving RWD landscape, we thought it appropriate to begin to broadly assess the use of real world data.
Our survey is open now.
While the impact and legacy of the very much on-going pandemic most acutely hits those infected, their families and friends, and the frontline healthcare providers, one clear legacy of this extraordinary moment will be how it helped show real world data is a critical component of the life sciences industry’s future.
There is now a daily public consumption of complex, evolving real world health data to an extraordinary degree. From the original goal of “flattening the curve” to rolling averages, and rates for testing, cases, hospitalizations, deaths, vaccinations and more, data inserts itself into the daily discourse up, down, and across society. At the same time, real world data continues to increasingly impact virtually every facet of what the life sciences industry does - from R&D strategy to commercialization – across therapeutic areas.
Again, your support of our survey is appreciated.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
